World Health Organisation (WHO) Director-General Tedros Adhanom Ghebreyesus delivers a speech on the opening day of 75th World Health Assembly of the World Health Organisation (WHO) in Geneva on May 22, 2022.
Jean-Guy Python—AFP/Getty Images
July 14, 2022 10:39 AM EDT

A generic antidepressant and a gout medicine that garnered some popularity as COVID-19 treatments shouldn’t be used for mild infection because there’s no evidence they help, according to a panel of experts advising the World Health Organization.

The drugs, fluvoxamine and colchicine, could potentially cause harm, the group of experts said in the BMJ medical journal Thursday. The panel didn’t give advice for severe illness, saying there was a lack of data.

The two medicines “are commonly used, inexpensive drugs that have received considerable interest as potential COVID-19 treatments during the pandemic,” the WHO said.

Read More: COVID-19 Reinfections May Be Common—But They’re Not Harmless

Fluvoxamine is used for depression and obsessive-compulsive disorders and has been prescribed for almost 30 years. The medicine was found to slightly reduce the risk of hospitalization in COVID in a study published in the Lancet Global Health journal last October.

The WHO’s decision reflects uncertainty about how the two drugs would work against COVID-19 in the body, and evidence of little or no effect on survival and other measures such as risk of hospital admission and need for mechanical ventilation, according to the agency.

The experts said they considered data from three randomized controlled trials involving over 2,000 patients for fluvoxamine and seven such tests with 16,484 patients for colchicine.

More Must-Read Stories From TIME

Contact us at letters@time.com.

Read More From TIME
You May Also Like
EDIT POST